Publications

  1. Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff B, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M. A Prospective Genome-Wide Study of Prostate Cancer Metastases Reveals Association of Wnt Pathway Activation and Increased Cell Cycle Proliferation with Primary Resistance to Abiraterone Acetate-Prednisone. Ann Oncol. 2017 Oct 23 [Epub ahead of print]
    View PubMed
  2. Le-Rademacher J, Kanwar R, Seisler D, Pachman DR, Qin R, Abyzov A, Ruddy KJ, Banck MS, Lavoie Smith EM, Dorsey SG, Aaronson NK, Sloan J, Loprinzi CL, Beutler AS. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Support Care Cancer. 2017 Jun 20 Epub 2017 June 20
    View PubMed
  3. Haddad T, Qin R, Lupu R, Satele D, Eadens M, Goetz MP, Erlichman C, Molina J. A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2017 Jun; 79: (6)1221-1227.
    View PubMed
  4. Yin J, Qin R, Sargent DJ, Erlichman C, Shi Q. A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups. J Biopharm Stat. 2017 Apr 27; 1-12.
    View PubMed
  5. Yin J, Qin R, Ezzalfani M, Sargent DJ, Mandrekar SJ. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles. Stat Med. 2017 Jan 15; 36: (1)67-80.
    View PubMed
  6. Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017 Jan 03; 317: (1)48-58.
    View PubMed
  7. Pachman DR, Qin R, Seisler D, Smith EM, Kaggal S, Novotny P, Ruddy KJ, Lafky JM, Ta LE, Beutler AS, Wagner-Johnston ND, Staff NP, Grothey A, Dougherty PM, Cavaletti G, Loprinzi CL. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer. 2016 Dec; 24 (12):5059-5068 Epub 2016 Aug 18
    View PubMed
  8. Jatoi A, Qin R, Satele D, Dakhil S, Kumar P, Johnson DB, Thomas SP, Stella PJ, Castillo J, Li M, Fernandez-Zapico M. "Enjoy glass of wine before eating:" a randomized trial to test the orexigenic effects of this advice in advanced cancer patients. Support Care Cancer. 2016 Sep; 24 (9):3739-46 Epub 2016 Apr 02
    View PubMed
  9. van Reesema LLS, Zheleva V, Winston JS, Jansen RJ, O'Connor CF, Isbell AJ, Bian M, Qin R, Bassett PT, Hinson VJ, Dorsch KA, Kirby BW, Van Sciver RE, Tang-Tan AM, Harden EA, Chang DZ, Allen CA, Perry RR, Hoefer RA, Tang AH. SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer. EBioMedicine. 2016 Sep; 11:183-198 Epub 2016 Aug 14
    View PubMed
  10. Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14; 375: (2)134-42.
    View PubMed
  11. Hart SN, Ellingson MS, Schahl K, Vedell PT, Carlson RE, Sinnwell JP, Barman P, Sicotte H, Eckel-Passow JE, Wang L, Kalari KR, Qin R, Kruisselbrink TM, Jimenez RE, Bryce AH, Tan W, Weinshilboum R, Wang L, Kohli M. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open. 2016 Apr 15; 6: (4)e010332.
    View PubMed
  12. Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, Lafky JM, Qin R, Grothey A, Loprinzi CL. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer. 2016 Mar; 24: (3)1071-8.
    View PubMed
  13. Hubbard JM, Kim G, Borad MJ, Johnson E, Qin R, Lensing J, Puttabasavaiah S, Wright J, Erlichman C, Grothey A. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Invest New Drugs. 2016 Feb; 34: (1)96-103.
    View PubMed
  14. Voge GA, Katusic SK, Qin R, Juhn YJ. Risk of Asthma in Late Preterm Infants: A Propensity Score Approach. J Allergy Clin Immunol Pract. 2015 Nov-Dec; 3: (6)905-10.
    View PubMed
  15. Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol. 2015 Oct 20; 33: (30)3416-22.
    View PubMed
  16. Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS, Ruddy KJ, Pleticha J, Lynch CA, Behrens RJ, Zuchner S, Loprinzi CL, Beutler AS. Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci. 2015 Oct 15; 357: (1-2)35-40.
    View PubMed
  17. Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich LL, Lafky JM, Loprinzi CL. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2015 Oct 10; 33: (29_suppl)176.
    View PubMed
  18. Kurtoglu M, Davarpanah NN, Qin R, Powles T, Rosenberg JE, Apolo AB. Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2015 Oct; 13: (5)410-20.
    View PubMed
  19. Park H, Qin R, Smith TJ, Atherton PJ, Barton DL, Sturtz K, Dakhil SR, Anderson DM, Flynn K, Puttabasavaiah S, Le-Lindqwister NA, Padula GD, Loprinzi CL. North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause. 2015 Jun; 22 (6):627-32
    View PubMed
  20. Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman C. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2015 May 10; 33: (14)1551-6.
    View PubMed
  21. Qin R, Smyrk TC, Reed NR, Schmidt RL, Schnelldorfer T, Chari ST, Petersen GM, Tang AH. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RASKi67HIF-1alpha pathway to predict survival in resectable pancreatic cancer. Br J Cancer. 2015 Feb 03; 112: (3)514-22.
    View PubMed
  22. Cartin-Ceba R, Hubmayr RD, Qin R, Peters S, Determann RM, Schultz MJ, Gajic O. Predictive value of plasma biomarkers for mortality and organ failure development in patients with acute respiratory distress syndrome. J Crit Care. 2015 Feb; 30(1):219.e1-7. Epub 2014 Sep 6
    View PubMed
  23. Knox JJ, Qin R, Strosberg JR, Tan B, Kaubisch A, El-Khoueiry AB, Bekaii-Saab TS, Rousey SR, Chen HX, Erlichman C. A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015 Feb; 33: (1)241-6.
    View PubMed
  24. Merchan JR, Qin R, Pitot H, Picus J, Liu G, Fitch T, Maples WJ, Flynn PJ, Fruth BF, Erlichman C. Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: A phase 2 consortium study. Cancer Chemother Pharmacol. 2015; 75(3):485-93.
    View PubMed
  25. Liu H, Tan AD, Qin R, Sargent DJ, Grothey A, Buckner JC, Schaefer PL, Sloan JA. Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag. 2015; 2 (2) Epub 2015 Apr 10
    View PubMed
  26. Kohli M, Wang L, Xie F, Sicotte H, Yin P, Dehm SM, Hart SN, Vedell PT, Barman P, Qin R, Mahoney DW, Carlson RE, Eckel-Passow JE, Atwell TD, Eiken PW, McMenomy BP, Wieben ED, Jha G, Jimenez RE, Weinshilboum R, Wang L. Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. PLoS One. 2015; 10: (12)e0145176.
    View PubMed
  27. Beutler AS, Kulkarni AA, Kanwar R, Klein CJ, Therneau TM, Qin R, Banck MS, Boora GK, Ruddy KJ, Wu Y, Smalley RL, Cunningham JM, Le-Lindqwister NA, Beyerlein P, Schroth GP, Windebank AJ, Zuchner S, Loprinzi CL. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol. 2014 Nov; 76: (5)727-37.
    View PubMed
  28. Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, Watanaboonyakhet P, Weiss M, Adams PT, Dockter TJ, Loprinzi CL, Alliance for Clinical Trials in Oncology. North Central Cancer Treatment GroupAlliance trial N08CA-the use of glutathione for prevention of paclitaxelcarboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014 Jun 15; 120: (12)1890-7.
    View PubMed
  29. Leenstra JL, Miller RC, Qin R, Martenson JA, Dornfeld KJ, Bearden JD, Puri DR, Stella PJ, Mazurczak MA, Klish MD, Novotny PJ, Foote RL, Loprinzi CL. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). J Clin Oncol. 2014 May 20; 32: (15)1571-7.
    View PubMed
  30. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CBAlliance). J Clin Oncol. 2014 Apr 01; 32: (10)997-1005.
    View PubMed
  31. Kadakia KC, Leal AD, Seisler DK, Qin R, Fee-Schroeder KC, Grendahl DC, Sorgatz KM, Loprinzi CL. Antiemetic prescribing practices using a computerized physician order entry system. Support Care Cancer. 2014 Jan; 22: (1)217-23.
    View PubMed
  32. Clark K, Sharma D, Qin R, Chute CG, Tao C. A use case study on late stent thrombosis for ontology-based temporal reasoning and analysis. J Biomed Semantics. 2014; 5: (1)49.
    View PubMed
  33. Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):477-83. Epub 2013 Jul 26.
    View PubMed
  34. Lavoie Smith, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: the reliability and validity of the european organization for research and treatment of cancer qlq-cipn20 questionnaire. Qual Life Res. 2013 Dec; 22(10):2787-99.
    View PubMed
  35. Jones G, Arthurs B, Kaya H, Macdonald K, Qin R, Fairbanks RK, Lamoreaux WT, Jawed I, Tward JD, Martincic D, Shivnani AT, Lee CM. Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis. Am J Clin Oncol. 2013 Oct; 36(5):500-4.
    View PubMed
  36. Schenk E, Hendrickson AE, Northfelt D, Toft DO, Ames MM, Menefee M, Satele D, Qin R, Erlichman C. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies. Invest New Drugs. 2013 Oct; 31: (5)1251-6.
    View PubMed
  37. Kumar SK, Jett J, Marks R, Richardson R, Quevedo F, Moynihan T, Croghan G, Markovic SN, Bible KC, Qin R, Tan A, Molina J, Kaufmann SH, Erlichman C, Adjei AA. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31: (5)1201-6.
    View PubMed
  38. Ezzalfani M, Zohar S, Qin R, Mandrekar SJ, Deley MC. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities. Stat Med. 2013 Jul 20; 32(16):2728-46. Epub 2013 Jan 21.
    View PubMed
  39. Yang HJ, Qin R, Katusic S, Juhn YJ. Population-based study on association between birth weight and risk of asthma: a propensity score approach. Ann Allergy Asthma Immunol. 2013 Jan; 110: (1)18-23.
    View PubMed
  40. Qin R, Kohli M. Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology. Pers. Med. 2013; 10(8):859-69.
  41. Clark K, Sharma D, Qin R, Jiang G, Chute CG, Tao C. Ontology-based temporal analysis for medical device adverse event- A use case study on Late Stent Thrombosis. CEUR Workshop Proceedings. 2013; 1114.
  42. Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC. A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer. Cancer Gene Ther. 2012 Dec; 19: (12)839-44.
    View PubMed
  43. Kohli M, Oberg AL, Mahoney DW, Riska SM, Zhang Y, Zenka RM, Sahasrabudhe DM, Qin R, Carlson R, Zhang S. Serum proteomics and ingenuity pathway analysis (IPA)-guided discovery of response markers to androgen ablation (AA) in prostate cancer. J Clin Oncol. 2012 Oct 20; 30: (30_suppl)11.
    View PubMed
  44. Albuquerque FN, Somers VK, Blume G, Miranda W, Korenfeld Y, Calvin AD, Qin R, Lopez-Jimenez F. Usefulness of epicardial adipose tissue as predictor of cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2012 Oct 15; 110: (8)1100-5.
    View PubMed
  45. Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Invest New Drugs. 2012 Oct; 30: (5)1934-41.
    View PubMed
  46. Huebner M, Kendrick M, Reid-Lombardo KM, Que F, Therneau T, Qin R, Donohue J, Nagorney D, Farnell M, Sarr M. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J Gastrointest Surg. 2012 May; 16 (5):920-6 Epub 2012 Mar 16
    View PubMed
  47. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, Aaronson NK, Satele DV, Mattar BI, Green NB, Loprinzi CL. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer. 2012 Mar; 20: (3)625-32.
    View PubMed
  48. Kohli M, Riska SM, Mahoney DW, Chai HS, Hillman DW, Rider DN, Costello BA, Qin R, Lamba J, Sahasrabudhe DM, Cerhan JR. Germline predictors of androgen deprivation therapy response in advanced prostate cancer. Mayo Clin Proc. 2012 Mar; 87: (3)240-6.
    View PubMed
  49. Hobday TJ, Qin R, Reidy DL, Moore MJ, Strosberg JR, Kaubisch A, Shah MH, Kindler HL, Lenz HJ, Chen HX, Erlichman C. Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). J Clin Oncol. 2012 Feb; 30: (4_suppl)260.
    View PubMed
  50. Pruthi S, Qin R, Terstreip SA, Liu H, Loprinzi CL, Shah TR, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL. A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. Menopause. 2012 Jan; 19: (1)48-53.
    View PubMed
  51. Jatoi A, Nieva JJ, Qin R, Loprinzi CL, Wos EJ, Novotny PJ, Moore DF Jr, Mowat RB, Bechar N, Pajon ER Jr, Hartmann LC. A pilot study of long-acting octreotide for symptomatic malignant ascites. Oncology. 2012; 82: (6)315-20.
    View PubMed
  52. Kohli M, Qin R, Jimenez R, Dehm SM. Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012; 2012:781459.
    View PubMed
  53. Jones JM, Qin R, Bardia A, Linquist B, Wolf S, Loprinzi CL. Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Palliat Med. 2011 Jul; 14: (7)810-4.
    View PubMed
  54. Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TR, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL. The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7. J Clin Oncol. 2011 Jun 20; 29: (18_suppl)CRA9015.
    View PubMed
  55. Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD 3rd, Kugler JW, Hoff KL, Reddy PS, Rowland KM Jr, Riepl M, Christensen B, Loprinzi CL. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011 Jun; 19: (6)833-41.
    View PubMed
  56. Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy SP, Haluska P. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest New Drugs. 2011 Jun; 29: (3)473-80.
    View PubMed
  57. Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TR, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL. The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7. J Clin Oncol. 2011 May 20; 29: (15_suppl)CRA9015.
    View PubMed
  58. Dueck AC, Sargent DJ, Novotny PJ, Decker PA, Nelson H, Qin R, Sloan JA. Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials. J Clin Oncol. 2011 May 20; 29: (15_suppl)6130.
    View PubMed
  59. Merchan JR, Pitot HC, Qin R, Liu G, Fitch TR, Maples WJ, Picus J, Erlichman C. Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma. J Clin Oncol. 2011 May 20; 29: (15_suppl)4548.
    View PubMed
  60. Morgan R, Oza AM, Qin R, Laumann KM, Mackay H, Strevel EL, Welch S, Sullivan D, Wenham RM, Chen HX, Doyle LA, Gandara DR, Erlichman C. A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: Ovarian cancer (OC) subset-A study of the Princess Margaret, Mayo, Southeast phase II, and California Cancer (CCCP) N01 Consortia NCI#8233. J Clin Oncol. 2011 May 20; 29: (15_suppl)5015.
    View PubMed
  61. Wang JK, Holubar SD, Wolff BG, Follestad B, O'Byrne MM, Qin R. Risk factors for splenic injury during colectomy: a matched case-control study. World J Surg. 2011 May; 35 (5):1123-9
    View PubMed
  62. Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, Ames MM, Limburg PJ, Cancer Prevention Network. Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila). 2011 Mar; 4: (3)347-53.
    View PubMed
  63. Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot HC, Tan W, Erlichman C, Vaishampayan UN. MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. J Clin Oncol. 2011 Mar; 29: (7_suppl)259.
    View PubMed
  64. Titler MG, Shever LL, Kanak MF, Picone DM, Qin R. Factors associated with falls during hospitalization in an older adult population. Res Theory Nurs Pract. 2011; 25(2):127-48.
    View PubMed
  65. Wolf SL, Qin R, Menon SP, Rowland KM Jr, Thomas S, Delaune R, Christian D, Pajon ER Jr, Satele DV, Berenberg JL, Loprinzi CL, North Central Cancer Treatment Group Study N05C5. Placebo-controlled trial to determine the effectiveness of a urealactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol. 2010 Dec 10; 28: (35)5182-7.
    View PubMed
  66. You YN, Wolff BG, Boardman LA, Riegert-Johnson DL, Qin R. Peutz-Jeghers syndrome: a study of long-term surgical morbidity and causes of mortality. Fam Cancer. 2010 Dec; 9 (4):609-16
    View PubMed
  67. Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Gene Ther. 2010 Nov; 17: (11)1325-32.
    View PubMed
  68. Mandrekar SJ, Qin R, Sargent DJ. Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges. Stat Med. 2010 May 10; 29: (10)1077-83.
    View PubMed
  69. Juhn YJ, Qin R, Urm S, Katusic S, Vargas-Chanes D. The influence of neighborhood environment on the incidence of childhood asthma: a propensity score approach. J Allergy Clin Immunol. 2010 Apr; 125: (4)838-843.e2.
    View PubMed
  70. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate. 2010 Mar 01; 70: (4)443-55.
    View PubMed
  71. Loprinzi CL, Qin R, Balcueva EP, Flynn KA, Rowland KM Jr, Graham DL, Erwin NK, Dakhil SR, Jurgens DJ, Burger KN. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol. 2010 Feb 01; 28: (4)641-7.
    View PubMed
  72. Kerr P, Shever L, Titler MG, Qin R, Kim T, Picone DM. The unique contribution of the nursing intervention pain management on length of stay in older patients undergoing hip procedures. Appl Nurs Res. 2010 Feb; 23(1):36-44. Epub 2009 Jan 15.
    View PubMed
  73. Malireddy K, Larson DW, Sandborn WJ, Loftus EV, Faubion WA, Pardi DS, Qin R, Gullerud RE, Cima RR, Wolff B, Dozois EJ. Recurrence and impact of postoperative prophylaxis in laparoscopically treated primary ileocolic Crohn disease. Arch Surg. 2010 Jan; 145(1):42-7.
    View PubMed
  74. Barton JG, Bois JP, Sarr MG, Wood CM, Qin R, Thomsen KM, Kendrick ML, Farnell MB. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg. 2009 Nov; 13 (11):2050-8 Epub 2009 Sept 09
    View PubMed
  75. Holubar SD, Wang JK, Wolff BG, Nagorney DM, Dozois EJ, Cima RR, O'Byrne MM, Qin R, Larson DW. Splenic salvage after intraoperative splenic injury during colectomy. Arch Surg. 2009 Nov; 144(11):1040-5.
    View PubMed
  76. Schoenleber SJ, Schnelldorfer T, Wood CM, Qin R, Sarr MG, Donohue JH. Factors influencing lymph node recovery from the operative specimen after gastrectomy for gastric adenocarcinoma. J Gastrointest Surg. 2009 Jul; 13 (7):1233-7 Epub 2009 Apr 15
    View PubMed
  77. Merchan JR, Pitot HC, Qin R, Liu G, Fitch TR, Picus J, Maples WJ, Erlichman C. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients. J Clin Oncol. 2009 May 20; 27: (15_suppl)5039.
    View PubMed
  78. Wolf SL, Qin R, Barton DL, Sloan JA, Liu H, Aaronson NK, Satele DV, Green NB, Mattar BI, Loprinzi CL. Relationship of sensory symptoms and motor function in patients with chemotherapy-induced peripheral neuropathy (CIPN) utilizing the EORTC QLQ CIPN20: NCCTG study N06CA. J Clin Oncol. 2009 May 20; 27: (15_suppl)9587.
    View PubMed
  79. Jones JM, Loprinzi CL, Qin R, Barton DL. Hot flash placebo responses: Related to baseline hot flash frequency? J Clin Oncol. 2009 May 20; 27: (15_suppl)9628.
    View PubMed
  80. Loprinzi CL, Qin R, Stella PJ, Rowland KM Jr, Graham DL, Erwin N, Dakhil SR, Jurgens DJ, Burger KN. Pregabalin for hot flashes in women: NCCTG trial N07C1. J Clin Oncol. 2009 May 20; 27: (15_suppl)9513.
    View PubMed
  81. Barton DL, Wos E, Qin R, Mattar B, Green N, Lanier K, Bearden J, Kugler J, Rowland K Jr, Loprinzi C. A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA. J Clin Oncol. 2009 May 20; 27: (15_suppl)9531.
    View PubMed
  82. Tsikitis VL, Larson DL, Wolff BG, Kennedy G, Diehl N, Qin R, Dozois EJ, Cima RR. Survival in stage III colon cancer is independent of the total number of lymph nodes retrieved. J Am Coll Surg. 2009 Jan; 208(1):42-7.
    View PubMed
  83. Qin R, Titler MG, Shever LL, Kim T. Estimating effects of nursing intervention via propensity score analysis. Nurs Res. 2008 Nov-Dec; 57: (6)444-52.
    View PubMed
  84. Schnelldorfer T, Sarr MG, Nagorney DM, Zhang L, Smyrk TC, Qin R, Chari ST, Farnell MB. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008 Jul; 143(7):639-46; discussion 646.
    View PubMed
  85. Kumar S, Marks RS, Richardson R, Quevedo F, Croghan GA, Markovic SN, Qin R, Tan AD, Molina JR, Erlichman CE, Adjei AA. A phase I study of the raf kinase/VEGF-R inhibitor sorafenib in combination with bortezomib in patients with advanced malignancy. J Clin Oncol. 2008 May 20; 26: (15_suppl)2569.
    View PubMed
  86. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008 Mar; 247(3):456-62.
    View PubMed
  87. Picone DM, Titler MG, Dochterman J, Shever L, Kim T, Abramowitz P, Kanak M, Qin R. Predictors of medication errors among elderly hospitalized patients. Am J Med Qual. 2008 Mar-Apr; 23(2):115-27. Epub 2008 Feb 27.
    View PubMed
  88. Shever L, Titler M, Herr P, Qin R, Kim T, Picone D. The effect of high Nursing surveillance on hospital cost. J Nurs Scholarship. 2008; 40:161-169.